Literature DB >> 23121125

Endothelial FOS expression and pre-eclampsia.

R M Mackenzie1, V C Sandrim, D M Carty, J D McClure, D J Freeman, A F Dominiczak, M W McBride, C Delles.   

Abstract

OBJECTIVE: To study gene expression profiles in human endothelial cells incubated with plasma from women who developed pre-eclampsia and women with normotensive pregnancies.
DESIGN: A case-control study.
SETTING: A longitudinal nested case-control study within three maternity units. POPULATION: A mixed obstetric population attending maternity hospitals in Glasgow.
METHODS: Plasma was obtained at both 16 and 28 weeks of gestation from 12 women: six women subsequently developed pre-eclampsia (cases) and six women, matched for age, body mass index (BMI) and parity, remained normotensive (controls). Human umbilical vein endothelial cells (HUVECs) were incubated with plasma for 24 hour before RNA isolation. MAIN OUTCOME MEASURES: Gene expression profiles were compared between the two gestational time points using Illumina(®) HumanHT-12 v4 Expression BeadChips. Differential mRNA expression observed in microarray experiments were validated using quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR), and gene networks were analysed using Ingenuity(®) pathway analysis.
RESULTS: There was a significant difference in the expression of 25 genes following incubation with plasma from controls, and an increase in the expression of 11 genes following incubation with plasma from cases, with no overlap between the two groups (false discovery rate, FDR < 0.05). There was a 3.74-fold (FDR < 0.001) increase in the expression of the c-Fos gene (FOS) when HUVECs were incubated with control plasma from 16 and 28 weeks of gestation, with no significant difference between the two time points with plasma from cases. Similar findings for FOS were obtained by qRT-PCR.
CONCLUSIONS: Plasma from women who subsequently develop pre-eclampsia appears to contain factors that lead to the dysregulation of FOS in endothelial cells during pregnancy. Reduced expression of c-Fos may lead to impaired vasculogenesis, and thereby contribute to the development of pre-eclampsia.
© 2012 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2012 RCOG.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23121125     DOI: 10.1111/1471-0528.12016

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  5 in total

1.  Involvement of Visceral Adipose Tissue in Immunological Modulation of Inflammatory Cascade in Preeclampsia.

Authors:  Katsuhiko Naruse; Juria Akasaka; Aiko Shigemitsu; Taihei Tsunemi; Natsuki Koike; Chiharu Yoshimoto; Hiroshi Kobayashi
Journal:  Mediators Inflamm       Date:  2015-05-31       Impact factor: 4.711

2.  Plasma from pre-eclamptic patients induces the expression of the anti-angiogenic miR-195-5p in endothelial cells.

Authors:  Valeria Cristina Sandrim; Mayara Caldeira Dias; Ana Lívia de Carvalho Bovolato; Jose E Tanus-Santos; Elenice Deffune; Ricardo C Cavalli
Journal:  J Cell Mol Med       Date:  2016-03-24       Impact factor: 5.310

3.  Molecular mechanisms underlying altered neurobehavioural development of female offspring of mothers with polycystic ovary syndrome: FOS-mediated regulation of neurotrophins in placenta.

Authors:  Fangfang Wang; Ningning Xie; Jue Zhou; Minchen Dai; Qing Zhang; Paul J Hardiman; Fan Qu
Journal:  EBioMedicine       Date:  2020-09-16       Impact factor: 8.143

4.  Risk factors for perinatal death in two different levels of care: a case-control study.

Authors:  Paula Maria Silveira Soares Moura; Izildinha Maestá; Lígia Maria Souza Suppo Rugolo; Luís Felipe Ramos Berbel Angulski; Antônio Prates Caldeira; José Carlos Peraçoli; Marilza Vieira Cunha Rudge
Journal:  Reprod Health       Date:  2014-01-30       Impact factor: 3.223

5.  Why does a high-fat diet induce preeclampsia-like symptoms in pregnant rats.

Authors:  Jing Ge; Jun Wang; Dan Xue; Zhengsheng Zhu; Zhenyu Chen; Xiaoqiu Li; Dongfeng Su; Juan Du
Journal:  Neural Regen Res       Date:  2013-07-15       Impact factor: 5.135

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.